Victory Capital Management Inc Monopar Therapeutics Transaction History

Victory Capital Management Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 07, 2020	SELL	$6.4 - $9.5 $2,201 - $3,268	-344 Closed	0 $0
Q1 2020 May 04, 2020	BUY	$5.06 - $22.0 $713 - $3,102	141 Added 69.46%	344 $2,000
Q4 2019 Feb 04, 2020	BUY	$16.6 - $27.0 $3,369 - $5,481	203 New	203 $3,000

Ticker MNPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,725,800
Market Cap $316M
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.